Trial Outcomes & Findings for A Study of Modified Stem Cells in Stable Ischemic Stroke (NCT NCT01287936)
NCT ID: NCT01287936
Last Updated: 2023-02-03
Results Overview
Number of subjects with TEAEs by maximum severity. The severity of all AEs was assessed by the Investigator using the World Health Organization (WHO) Toxicity Scale. For abnormalities not found elsewhere in the WHO table, the following scale was used to assign severity: Mild: Transient mild discomfort; no limitation in activity; no medical intervention/therapy required. Moderate: Mild-to-moderate limitation in activity; some assistance may be need. No or minimal medical intervention/therapy required. Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required; hospitalization or prolongation of current hospitalization possible. Life-threatening: Extreme limitation in activity, significant assistance required; significant medial intervention/therapy required; hospitalization or prolongation of current hospitalization or hospice care probable.
COMPLETED
PHASE1/PHASE2
18 participants
6 months
2023-02-03
Participant Flow
Participant milestones
| Measure |
SB623 Implant (2.5M)
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
|---|---|---|---|
|
Overall Study
STARTED
|
6
|
6
|
6
|
|
Overall Study
COMPLETED
|
6
|
5
|
5
|
|
Overall Study
NOT COMPLETED
|
0
|
1
|
1
|
Reasons for withdrawal
| Measure |
SB623 Implant (2.5M)
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
|---|---|---|---|
|
Overall Study
Lost to Follow-up
|
0
|
1
|
1
|
Baseline Characteristics
A Study of Modified Stem Cells in Stable Ischemic Stroke
Baseline characteristics by cohort
| Measure |
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
Total
n=18 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
60.0 years
STANDARD_DEVIATION 7.62 • n=99 Participants
|
67.2 years
STANDARD_DEVIATION 7.60 • n=107 Participants
|
56.8 years
STANDARD_DEVIATION 13.30 • n=206 Participants
|
61.3 years
STANDARD_DEVIATION 10.29 • n=7 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
11 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
7 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
6 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
18 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
5 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
Race (NIH/OMB)
White
|
3 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
5 Participants
n=206 Participants
|
12 Participants
n=7 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Region of Enrollment
United States
|
6 participants
n=99 Participants
|
6 participants
n=107 Participants
|
6 participants
n=206 Participants
|
18 participants
n=7 Participants
|
PRIMARY outcome
Timeframe: 6 monthsPopulation: Safety population includes all enrolled patients who have received study treatment and who have any post-baseline data.
Number of subjects with TEAEs by maximum severity. The severity of all AEs was assessed by the Investigator using the World Health Organization (WHO) Toxicity Scale. For abnormalities not found elsewhere in the WHO table, the following scale was used to assign severity: Mild: Transient mild discomfort; no limitation in activity; no medical intervention/therapy required. Moderate: Mild-to-moderate limitation in activity; some assistance may be need. No or minimal medical intervention/therapy required. Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required; hospitalization or prolongation of current hospitalization possible. Life-threatening: Extreme limitation in activity, significant assistance required; significant medial intervention/therapy required; hospitalization or prolongation of current hospitalization or hospice care probable.
Outcome measures
| Measure |
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
|---|---|---|---|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
Mild
|
1 Participants
|
1 Participants
|
0 Participants
|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
Moderate
|
3 Participants
|
2 Participants
|
4 Participants
|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
Severe
|
1 Participants
|
3 Participants
|
2 Participants
|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
Life threatening
|
1 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: Intent-to-Treat (ITT) Population: Included all randomized subjects who completed the surgery treatment procedure (18 subjects).
The ESS is the sum of 14 items that are used to assess a patient who has recently had a stroke. These 14 items are level of consciousness, comprehension, speech, visual field, gaze, facial movement, arm in outstretched position, arm raising, extension of the wrist, fingers, leg maintained in position, leg flexing, dorsiflexion of the foot, and gait. A certain number of points are given for each parameter. The range of the total score of ESS is 0 - 100, with a completely normal person having a score of 100 and maximally affected person with a score of zero.
Outcome measures
| Measure |
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
|---|---|---|---|
|
Change in the European Stroke Scale (ESS) Total Score From Baseline at Month 6
|
7.67 Change in score on a scale from baseline
Standard Deviation 8.140
|
4.50 Change in score on a scale from baseline
Standard Deviation 5.244
|
7.75 Change in score on a scale from baseline
Standard Deviation 10.012
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: Intent-to-Treat (ITT) Population: Included all randomized subjects who completed the surgery treatment procedure (18 subjects).
The ESS motor function score is a sum of the selected items: facial movement, arm in outstretched position, arm raising, extension of wrist, fingers, leg maintained in position, leg flexing, dorsiflexion of foot, and gait. A completely normal person will have a score of 66. The maximally affected person will have a score of zero.
Outcome measures
| Measure |
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
|---|---|---|---|
|
Change in the European Stroke Scale (ESS) Motor Function Total Score From Baseline at Month 6
|
6.33 Change in score on a scale from baseline
Standard Deviation 6.186
|
3.67 Change in score on a scale from baseline
Standard Deviation 3.933
|
6.25 Change in score on a scale from baseline
Standard Deviation 5.560
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: Intent-to-Treat (ITT) Population: Included all randomized subjects who completed the surgery treatment procedure (18 subjects).
The NIHSS is a standardized method used to measure the level of impairment caused by a stroke. The scale consists of 11 items that measure several aspects of brain function, including consciousness, vision, sensation, movement, speech, and language. A certain number of points are given for each impairment uncovered during a focused neurological examination. A maximal score of 42 represents the most severe and devastating stroke with 0=no stroke, 1-4=minor stroke, 5-15=moderate stroke, 15-20=moderate/severe stroke, and 21-42=severe stroke.
Outcome measures
| Measure |
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
|---|---|---|---|
|
Change in the National Institutes of Health Stroke Scale (NIHSS) Total Score From Baseline at Month 6
|
-2.00 change in score on a scale from baseline
Standard Deviation 1.265
|
-0.83 change in score on a scale from baseline
Standard Deviation 1.472
|
-2.50 change in score on a scale from baseline
Standard Deviation 3.512
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: Intent-to-Treat (ITT) Population: Included all randomized subjects who completed the surgery treatment procedure (18 subjects).
The NIHSS is a standardized method used to measure the level of impairment caused by a stroke. The NIHSS Motor Function Total Score consists of 3 items: motor arm, motor leg, and limb ataxia, with 0 = no stroke and a maximal score of 18 = most severe impairment for motor function.
Outcome measures
| Measure |
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
|---|---|---|---|
|
Change in the National Institutes of Health Stroke Scale (NIHSS) Motor Function Total Score From Baseline at Month 6
|
-1.33 change in score on a scale from baseline
Standard Deviation 0.816
|
-0.83 change in score on a scale from baseline
Standard Deviation 1.472
|
-1.00 change in score on a scale from baseline
Standard Deviation 1.414
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: Intent-to-Treat (ITT) Population: Included all randomized subjects who completed the surgery treatment procedure (18 subjects).
The mRS is a commonly used scale for measuring the degree of disability in daily activities for patients who have suffered a stroke. The mRS is an ordinal scale from 0 (no symptoms at all) to 5 (severe disability; requiring constant nursing care and attention, bedridden, incontinent) with a sixth category of death.
Outcome measures
| Measure |
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
|---|---|---|---|
|
Change in the Modified Rankin Scale (mRS) Response From Baseline at Month 6
|
0 Change in score on a scale from baseline
Standard Deviation 0
|
-0.17 Change in score on a scale from baseline
Standard Deviation 0.408
|
-0.25 Change in score on a scale from baseline
Standard Deviation 0.500
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: Intent-to-Treat (ITT) Population: Included all randomized subjects who completed the surgery treatment procedure (18 subjects).
The Fugl-Meyer Scale is a stroke-specific, performance-based impairment index. The scale is comprised of 5 domains (motor score, sensation, balance, joint range of motion, and joint pain) with 155 items in total. Scoring is based on direct observation of performance. Scale items in all 5 domains are scored on the basis of ability to complete the item using a 3-point Likert-type ordinal scale, where 0=cannot perform, 1=performs partially, and 2=performs fully. Points are divided among the domains: (a) Motor performance \[0 (hemiplegia) - 100 (normal motor performance) points\]; (b) Balance \[0-14 points: 6 for sitting; 8 for standing\]; (c) Sensation \[0-24 points: 8 for light touch; 16 for position sense\]; (d) Joint range of motion \[0-44 points\]; (e) Joint pain \[0-44 points\]. For all domains, a maximally affected person will score 0 while a fully functional person will have the highest score. All items are summed to provide a minimum score of 0 and a maximum score of 226.
Outcome measures
| Measure |
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
|---|---|---|---|
|
Change in the Fugl-Meyer Total Score From Baseline at Month 6
|
18.33 Change in score on a scale from baseline
Standard Deviation 13.721
|
17.70 Change in score on a scale from baseline
Standard Deviation 7.589
|
23.75 Change in score on a scale from baseline
Standard Deviation 21.975
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: Intent-to-Treat (ITT) Population: Included all randomized subjects who completed the surgery treatment procedure (18 subjects).
The FMMS is used as a clinical measure of body function impairment after stroke that assesses several dimensions of motor impairment, including range of motion in upper and lower limbs, reflex activity, volitional movement, and coordination. The FMMS motor total score ranged from 0 (hemiplegia) to a maximum of 100 points (normal motor performance), and is comprised of a 33-item upper extremity subscale (UE-FMMS) and the 17-item lower extremity subscale (LE-FMMS). Items were scored on a 3-point ordinal scale: 0= cannot perform; 1= partial motion; 2= full motion Individual items are summed to determine scores for the 2 subscale scores, as well as a motor total score (total of the 2 subscales UE-FMMS and LE-FMMS). As a result, the UE-FMMS subscale score ranged from 0 to 66 and the LE-FMMS subscale score ranged from 0 to 34. A maximally affected person will have a score of 0 while a fully functional person will have the highest score (i.e., 34 for LE-FMMS, 66 for UE-FMMS, 100 for FMMS)
Outcome measures
| Measure |
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
|---|---|---|---|
|
Change in the Fugl-Meyer Motor Total Score (FMMS) Total Score From Baseline at Month 6
|
8.17 Change in score on a scale from baseline
Standard Deviation 10.834
|
8.67 Change in score on a scale from baseline
Standard Deviation 4.633
|
17.50 Change in score on a scale from baseline
Standard Deviation 20.339
|
SECONDARY outcome
Timeframe: 6 monthsThe Fugl-Meyer Upper Extremity subscale (UE-FMMS) is comprised of 33 items that assess several dimensions of motor impairment, including range of motion in upper limbs, reflex activity, volitional movement, and coordination. Scoring is based on direct observation of performance and is scored using a 3-point ordinal scale, where 0=cannot perform; 1=partial motion; and 2=full motion Individual items are summed to provide ranging from 0 (minimum) to 66 (maximum). A maximally affected person will have a score of 0 while a fully functional person will a score of 66.
Outcome measures
| Measure |
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
|---|---|---|---|
|
Change in the Fugl-Meyer Upper Extremity Motor Function Total Score From Baseline at Month 6
|
4.00 Change in score on a scale from baseline
Standard Deviation 7.321
|
4.50 Change in score on a scale from baseline
Standard Deviation 3.017
|
11.25 Change in score on a scale from baseline
Standard Deviation 15.370
|
SECONDARY outcome
Timeframe: 6 monthsThe Fugl-Meyer Lower Extremity subscale (LE-FMMS) is comprised of 17 items that assess several dimensions of motor impairment, including range of motion in lower limbs, reflex activity, volitional movement, and coordination. Scoring is based on direct observation of performance and is scored using a 3-point ordinal scale, where 0=cannot perform; 1=partial motion; and 2=full motion Individual items are summed to provide ranging from 0 (minimum) to 34 (maximum). A maximally affected person will have a score of 0 while a fully functional person will a score of 34.
Outcome measures
| Measure |
SB623 Implant (2.5M)
n=6 Participants
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
n=6 Participants
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
n=6 Participants
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
|---|---|---|---|
|
Change in the Fugl-Meyer Lower Extremity Motor Function Total Score From Baseline at Month 6
|
4.17 Change in score on a scale from baseline
Standard Deviation 4.355
|
4.17 Change in score on a scale from baseline
Standard Deviation 3.061
|
6.25 Change in score on a scale from baseline
Standard Deviation 5.315
|
Adverse Events
SB623 Implant (2.5M)
SB623 Implant (5.0M)
SB623 Implant (10.0M)
Serious adverse events
| Measure |
SB623 Implant (2.5M)
n=6 participants at risk
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
n=6 participants at risk
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
n=6 participants at risk
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
|---|---|---|---|
|
Nervous system disorders
Carotid artery stenosis
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Nervous system disorders
Convulsion
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Nervous system disorders
Transient ischaemic attack
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Infections and infestations
Pneumonia
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Infections and infestations
Sepsis
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
Other adverse events
| Measure |
SB623 Implant (2.5M)
n=6 participants at risk
2.5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (5.0M)
n=6 participants at risk
5 million SB623 cells
SB623: SB623, a modified stem-cell product
|
SB623 Implant (10.0M)
n=6 participants at risk
10 million SB623 cells
SB623: SB623, a modified stem-cell product
|
|---|---|---|---|
|
Nervous system disorders
Headache
|
66.7%
4/6 • 6 months
|
66.7%
4/6 • 6 months
|
50.0%
3/6 • 6 months
|
|
Nervous system disorders
Muscle spasticity
|
33.3%
2/6 • 6 months
|
16.7%
1/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Nervous system disorders
Convulsion
|
16.7%
1/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Nervous system disorders
Dizziness
|
16.7%
1/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Nervous system disorders
Hypoaesthesia
|
16.7%
1/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Nervous system disorders
Pneumocephalus
|
0.00%
0/6 • 6 months
|
33.3%
2/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Nervous system disorders
Carotid artery stenosis
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Nervous system disorders
Muscle contractions involuntary
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Nervous system disorders
Myoclonus
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Nervous system disorders
Presyncope
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Nervous system disorders
Pseudobulbar palsy
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Nervous system disorders
Subdural hygroma
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Nervous system disorders
Transient ischaemic attack
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Nervous system disorders
Unresponsive to stimuli
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Injury, poisoning and procedural complications
Procedural headache
|
33.3%
2/6 • 6 months
|
0.00%
0/6 • 6 months
|
50.0%
3/6 • 6 months
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.00%
0/6 • 6 months
|
33.3%
2/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Injury, poisoning and procedural complications
Extradural haematoma
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Injury, poisoning and procedural complications
Incision site erythema
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Injury, poisoning and procedural complications
Incision site pain
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Injury, poisoning and procedural complications
Postoperative fever
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Injury, poisoning and procedural complications
Wound
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Injury, poisoning and procedural complications
Wound complication
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/6 • 6 months
|
50.0%
3/6 • 6 months
|
50.0%
3/6 • 6 months
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/6 • 6 months
|
33.3%
2/6 • 6 months
|
33.3%
2/6 • 6 months
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/6 • 6 months
|
33.3%
2/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Gastrointestinal disorders
Proctalgia
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Gastrointestinal disorders
Tooth loss
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
33.3%
2/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
33.3%
2/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
16.7%
1/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Musculoskeletal and connective tissue disorders
Mobility decreased
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Musculoskeletal and connective tissue disorders
Tendonitis
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
General disorders
Fatigue
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
33.3%
2/6 • 6 months
|
|
General disorders
Gait disturbance
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
General disorders
Influenza like illness
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
General disorders
Neurological complication associated with device
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
General disorders
Pain
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
General disorders
Pyrexia
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
General disorders
Vessel puncture site bruise
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Infections and infestations
Urinary tract infection
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
33.3%
2/6 • 6 months
|
|
Infections and infestations
Pneumonia
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
33.3%
2/6 • 6 months
|
|
Infections and infestations
Candidiasis
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Infections and infestations
Cystitis
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Infections and infestations
Diverticulitis
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Infections and infestations
Nasopharyngitis
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Infections and infestations
Sepsis
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Infections and infestations
Vulvovaginal mycotic infection
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Investigations
Blood glucose increased
|
33.3%
2/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Investigations
C-reactive protein increased
|
16.7%
1/6 • 6 months
|
16.7%
1/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Investigations
Alanine aminotransferase increased
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Investigations
Aspartate aminotransferase increased
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Investigations
Blood magnesium decreased
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Investigations
Blood pressure increased
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Investigations
Blood triglycerides increased
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Investigations
Lipids increased
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Investigations
Low density lipoprotein increased
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Investigations
Non-high-density lipoprotein cholesterol increased
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Investigations
Weight increased
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Blood and lymphatic system disorders
Neutropenia
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Psychiatric disorders
Depression
|
0.00%
0/6 • 6 months
|
33.3%
2/6 • 6 months
|
33.3%
2/6 • 6 months
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Psychiatric disorders
Dissociation
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Psychiatric disorders
Emotional distress
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Psychiatric disorders
Panic attack
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/6 • 6 months
|
33.3%
2/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Skin and subcutaneous tissue disorders
Skin discolouration
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Vascular disorders
Hypertension
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Vascular disorders
Hypotension
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
16.7%
1/6 • 6 months
|
|
Renal and urinary disorders
Urinary incontinence
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
|
Reproductive system and breast disorders
Prostatomegaly
|
16.7%
1/6 • 6 months
|
0.00%
0/6 • 6 months
|
0.00%
0/6 • 6 months
|
Additional Information
Bijan Nejadnik M.D.; Chief Medical Officer
SanBio, Inc.
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place